1. Home
  2. BDRX vs ARTL Comparison

BDRX vs ARTL Comparison

Compare BDRX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

N/A

Current Price

$2.31

Market Cap

1.6M

Sector

Health Care

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$2.14

Market Cap

1.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BDRX
ARTL
Founded
2000
2011
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6M
1.4M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
BDRX
ARTL
Price
$2.31
$2.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.0M
23.9K
Earning Date
09-11-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.52
52 Week High
$8.94
$179.19

Technical Indicators

Market Signals
Indicator
BDRX
ARTL
Relative Strength Index (RSI) 58.09 32.52
Support Level $0.70 $2.05
Resistance Level $3.50 $6.81
Average True Range (ATR) 0.32 0.20
MACD 0.02 0.06
Stochastic Oscillator 53.86 2.61

Price Performance

Historical Comparison
BDRX
ARTL

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: